Arthneeti

Poly Medicure Q1 FY27 Share Price & Earnings Call Analysis

₹1,449.50-0.85% today
Market cap
₹14,691 Cr
P/E
45.90
ROE
9.02%
PEG
2.96
Price to sales
7.36
Debt to equity
0.11
52W high / low
₹2,063 / ₹1,191
Sales growth (5Y)
19.01%
EBITDA margin
23.10%
Net profit margin
14.06%
Promoter holding
62.42%
Sales (last year)
₹1,997 Cr

Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.[1]

Guidance scorecard · Q1 FY27 call

What Poly Medicure Ltd's management guided
and where it ranks in Healthcare Equipment & Supplies

#8of 13 in
Healthcare Equipment & Supplies
Revenue10–20%MarginsFlatCapexPlannedFundraisingWhat management saidOrder bookRising

RevenueQ1 FY27 call

10–20%
  • The company aims to double its revenue by 2030, implying an 18% compounded annual growth over four years, with about 80% organic and 20% inorganic growth.
  • Domestic business is expected to grow over 20%, and international business over 15% for FY27.
  • Europe and Southeast Asia markets are key growth drivers currently, with Europe showing 17%+ growth in Q1.
  • Middle East orders are strong but delayed due to logistics; growth expected once regional situation improves.
  • Approximately 25 new products are in the pipeline for CE marking, expected to launch in the next 3-4 months, augmenting export growth.
  • Renal segment faced a slight de-growth (~3% in Q1) due to competition and pricing pressures but anticipates recovery post government antidumping actions.

2 more points from Poly Medicure Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Poly Medicure Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Board has allocated funds for expansion both organic and inorganic, including the recent acquisition in Brazil to expand direct sales presence.
  • Focus on technologies around three critical businesses: cardiology, oncology, and orthopedics, and adjacent technologies.
  • Capex planned at two plants under construction: one in Faridabad and one in Noida for medical devices.
  • Expected capex spend for FY27 is between INR 200 crores to INR 225 crores.

2 more points from Poly Medicure Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Poly Medicure Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

Rising
  • The Middle East order book is described as "pretty strong," indicating robust demand.
  • There is a current inability to ship products to the Middle East due to logistics and infrastructure bottlenecks related to the ongoing West Asia crisis.
  • Orders are piling up at ports or in factories because of disrupted shipping schedules, especially container shortages for Middle East ports.

2 more points from Poly Medicure Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Healthcare Equipment & Supplies ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Q-Line BiotechGood growth
    3
See all potential multibaggersWhere does Poly Medicure Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Healthcare Equipment & Supplies companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Flat₹627 Cr21.4
240%+Flat₹147 Cr16.8
3Q-Line Biotech20–40%Up 2%+₹1,467 Cr25.9
420–40%Flat₹18,144 Cr83.6
520–40%Flat₹173 Cr35.0
610–20%Up 2%+₹170 Cr18.8

Sign up free to see every company in the sector ranking and track Poly Medicure Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Equipment & Supplies ranking

Financials of Poly Medicure Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Poly Medicure Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +307321337340378385420424441403444494535
Expenses +224234253249282281305310321298329382424
Operating Profit8387849096104115114119106115111110
OPM %27%27%25%27%26%27%27%27%27%26%26%23%21%
Other Income +9141517151727242743352119
Interest2223333323366
Depreciation15161616162021212123252938
Profit before tax7583818892981181131231231229885
Tax %22%24%23%26%26%25%26%25%25%24%25%27%24%
Net Profit +59636265687487859293927165
EPS in Rs6.136.546.486.787.127.718.638.419.069.199.067.006.54

Financials of Poly Medicure Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +3904114545196106877859221,1151,3751,6691,875
Expenses +3043233613974795205697078471,0141,2141,433
Operating Profit868893122131166216215267361455442
OPM %22%21%21%23%22%24%28%23%24%26%27%24%
Other Income +288141620212240386094119
Interest1010812142011611141418
Depreciation1921242937414854576383116
Profit before tax85657597100126180195237344453427
Tax %27%27%27%27%35%24%25%25%25%25%25%25%
Net Profit +624855716596136147179258339321
EPS in Rs7.075.476.258.007.4110.8614.1715.2818.6926.9133.4131.78
Dividend Payout %18%27%40%25%27%18%18%16%16%11%10%11%

Financials of Poly Medicure Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital222244444444484848485151
Reserves1742072272943373919181,0401,1941,4222,7153,055
Borrowings +7982101133161207137127149174180354
Other Liabilities +89768594112126121163187215246459
Total Liabilities3643874575656547671,2241,3771,5771,8593,1923,919
Fixed Assets +1651822072653063634264886358671,0841,702
CWIP1014201819252143787610191
Investments443178253543461261671,077755
Other Assets +1851872272643213544224997387489301,371
Total Assets3643874575656547671,2241,3771,5771,8593,1923,919

Financials of Poly Medicure Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +63635675106131119123191266240246
Cash from Investing Activity +-59-31-56-88-101-109-436-85-179-241-1,194-225
Cash from Financing Activity +-6-31-016-5-21317-35-13-2095120
Net Cash Flow-21031103-15-341
Free Cash Flow1331-0-7312524-31-48-9-89-59
CFO/OP101%88%79%80%102%100%75%80%93%94%73%79%

Financials of Poly Medicure Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days5974777977687282777276103
Inventory Days148114194161186241217218237205233265
Days Payable1017613196123142111115105897175
Cash Conversion Cycle106111140144139166179185209188239294
Working Capital Days2535557156427481695474249
ROCE %30%26%24%26%22%25%22%17%18%24%20%14%

Guidance history

How Poly Medicure Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatPlanned—Rising
Q4 FY26 call →10–20%FlatPlanned——
Q3 FY26 call →20–40%FlatPlanned——
Q2 FY26 call →10–20%FlatPlannedPlanned—

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

19out of 100

Momentum score · price trend

19 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−26.6%30%
Last 6 months−4.1%49%
Last 3 months−14.8%33%

The price is 54.2% below its all-time high of ₹3,162.7 (1 Nov 2024). Stocks more than 20% below their peak have their score halved, so 38 became 19.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Poly Medicure Ltd: 0.4 × 30 + 0.4 × 49 + 0.2 × 33 = 38, halved to 19 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Poly Medicure Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • Galaxy Medicare (Q2 FY27)

    Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee

  • Nureca Ltd (Q2 FY27)

    Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's

  • Aprameya Engineering Ltd (Q2 FY26)

    H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26

  • Nureca Ltd (Q2 FY26)

    Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec

Compare:vs Molbio Diagnostivs Sahajanand Medical Technologies Ltdvs Fischer Medical Ventures Ltd